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Aberrant regulation of CD44, a transmembrane glyco-
protein, has been implicated in the growth and metas-
tasis of numerous tumors. Although both CD44 overex-
pression and loss have been implicated in tumor
progression, the mechanism of CD44 down-regulation in
these tumor types is not known. By immunoblot and
reverse transcription-polymerase chain reaction analy-
sis we determined that a cervical carcinoma cell line,
C33A, lacks CD44 expression. To determine how CD44 is
down-regulated in C33A cells, we utilized cell fusions of
C33A cells with a CD44-expressing cell line (SAOS-2). We
found that SAOS-2 fusion restored CD44 expression in
C33A cells, suggesting that a trans-acting factor present
in SAOS-2 cells promotes CD44 production. C33A cells
are BRG-1-deficient, and we found that CD44 was absent
in another BRG-1-deficient tumor cell line, indicating
that loss of BRG-1 may be a general mechanism by which
cells lose CD44. Reintroduction of BRG-1 into these cells
restored CD44 expression. Furthermore, disruption of
BRG-1 function through the use of dominant-negative
BRG-1 demonstrated the requirement of BRG-1 in CD44
regulation. Finally, we show that Cyclin E overexpres-
sion resulted in the attenuation of CD44 stimulation,
which is consistent with previous observations that Cy-
clin E can abrogate BRG-1 action. Taken together, these
results suggest that BRG-1 is a critical regulator of CD44
expression, thus implicating SWI/SNF components in
the regulation of cellular adhesion and metastasis.
The CD44 family of transmembrane glycoproteins has been
implicated in cell-cell and cell-matrix adhesion, cell growth,
and metastasis (1–3). A number of different CD44 proteins are
produced through alternative RNA splicing, and these proteins
are extensively modified. Many tumors express higher than
normal levels of total CD44 protein as well as splice variants
that do not occur in normal cells (1, 3, 4). How CD44 expression
is regulated in normal cells and in tumors is poorly understood.
A role for CD44 in tumor progression has been documented
in numerous clinical and experimental studies (1, 2). Ectopic
expression of some forms of CD44 can enhance metastasis and
tumor growth both in vitro and in vivo (5–7). It is believed that
CD44 expression in some tumors increases as the tumor be-
comes more proliferative and invasive (1). These findings sug-
gest that CD44 might be regulated by environmental or genetic
factors that have been shown to contribute to cancer progres-
sion. The expression of activated oncogenes like v-Ras, v-Src,
and v-Fos, which promote transformation and invasion, have
been reported to induce CD44 expression (8–10). In addition,
the epidermal growth factor receptor has also been shown to
stimulate CD44 (10, 11).
In contrast to studies that correlate CD44 overexpression
with cancer progression, a significant number of reports also
indicate that loss of CD44 expression can contribute to tumor-
igenesis (12). Specifically, it has been shown that loss of CD44
in cervical carcinomas, neuroblastomas, prostate carcinomas,
melanomas, and small cell lung carcinomas correlates with
increased aggressiveness of these tumors (13–17). It has been
hypothesized that loss of CD44 may facilitate the abrogation of
epithelial-mesenchymal interactions in some tumors, leading
to a more metastatic phenotype (4, 12). Unlike positive regu-
lators of CD44, no activity has been identified that leads to loss
of CD44 expression.
In the present study, we have identified the Brahma-related
gene, BRG-1,1 as a critical regulator of CD44 expression.
BRG-1 is a component of the SWI/SNF complex that regulates
gene transcription through ATPase-dependent remodeling of
chromatin (18–21). BRG-1 has been shown to inhibit the tran-
scription of a subset of genes involved in cancer such as Cyclin
A and c-fos (22–25). In addition, BRG-1 can facilitate estrogen
receptor, glucocorticoid receptor, c-Myc, and BRCA1-mediated
transcription (26–30).
We demonstrate that loss of BRG-1 correlates with a lack of
CD44 expression in several cell lines. Reintroduction of BRG-1
restored expression of CD44 in BRG-1-deficient cells, suggest-
ing that BRG-1 regulates basal CD44 levels. Moreover, we
show that functional BRG-1 is required for stimulating CD44,
because dominant-negative BRG-1 inhibits CD44 production.
In addition, we show that Cyclin E can antagonize BRG-1
regulation of CD44. As such, this report provides the first
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evidence that the SWI/SNF complex regulates genes involved
in cell adhesion and cancer metastasis and suggests that
BRG-1 loss in human tumors contributes to the formation of a
metastatic phenotype.
MATERIALS AND METHODS
Cells, Cell fusions, Plasmids, and Transfection—C33A, SAOS-2,
MCF-7, U87, PC3, U2OS, RD, and SW13 cells were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10% heat-in-
activated fetal bovine serum, 100 units/ml penicillin-streptomycin, and
2 mM L-glutamine at 37 °C in 5% CO2. 3T3 cells (BO5-1) were grown in
Dulbecco’s modified Eagle’s medium supplemented with 10% heat-in-
activated calf serum (Calbiochem), 100 units/ml penicillin-streptomy-
cin, 2 mM L-glutamine, 350 units of Hygromycin B, and 0.12 mg/ml
Geneticin either in the presence or absence of 2 mg/ml tetracycline (28).
Plasmids were transfected using the calcium phosphate method (31).
Antibiotic-resistant C33A and SAOS-2 cells were generated as previ-
ously described (32). The following plasmids: CMV-NEO, pBabe-Puro,
Cyclin E, PSM-RB, and BRG-1 have been previously described (33–36).
The cell fusions were generated as previously described (32).
Immunoblotting—Approximately 1 3 106 C33A and SW13 cells were
plated in 10-cm dishes 24 h before transfection. C33A and SW13 cells
were cotransfected with effectors and the puromycin-selectable plasmid
(pBabe-Puro). Transfected cells were subsequently selected with 2.5
mg/ml puromycin (Sigma) for 48–72 h and then harvested for immuno-
blot analysis. To isolate BRG-1, total protein was isolated from subcon-
fluent cultures using an 8 M urea extraction (8 M urea, 0.1 M NaH2PO4,
10 mM Tris, pH 8). For immunoblotting, cells were trypsinized and
subsequently washed with PBS. C33A and SW13 cell pellets were
resuspended in radioimmune precipitation buffer supplemented with
the following protease inhibitor mixture (10 mg/ml, 1,10-phenanthro-
line, 10 mg/ml aprotinin, 10 mg/ml leupeptin, and 1 mM phenylmeth-
ylsulfonyl fluoride) and incubated for 15 min on ice. The lysates were
briefly sonicated and then centrifuged for 10 min at 20,000 3 g at 4 °C.
The lysates were then separated via SDS-polyacrylamide gel electro-
phoresis and then transferred onto Immobilon-P membranes (Milli-
pore). The membranes were then incubated with either of the following
antibodies: anti-CD44 (Hermes 3), anti-Cdk4 (clone H22, Santa Cruz
Biotechnology), anti-Cyclin E (clone C19, Santa Cruz), anti-actin
(Sigma A-2066), anti-p53 (Dr. K. Fukasawa, University of Cincinnati,
College of Medicine, Cincinnati, OH), anti-pRB (Dr. J. Wang, Univer-
sity of California at San Diego, 851 polyclonal antibody), and anti-
BRG-1 (Dr. Weidong Wang, National Institutes of Health, Baltimore,
MD). The blots were then incubated with either horseradish peroxi-
dase-conjugated anti-rabbit or anti-mouse for 1 h at room temperature.
The antibody-antigen complex was detected by enhanced chemilumi-
nescence (ECL, Amersham Pharmacia Biotech). The levels of Cdk4 and
CD44 were quantitated using Metamorph software (Universal Imaging
Corp.).
Immunohistochemistry—Cells were fixed in 3.7% formaldehyde for
15 min and then either permeabilized (PBS, 0.3% Triton X-100, 5 mg/ml
bovine serum albumin) for p53 staining or directly blocked with 5%
normal goat serum for CD44 staining. The p53 antibody (1:100 dilution,
ab-6, Calbiochem) was detected with a rhodamine-conjugated anti-
mouse antibody. Human CD44 was probed with Hermes 3 (1:25, mono-
clonal antibody) and detected with a fluorescein-conjugated anti-mouse
antibody. Mouse CD44 was identified with IM7 (1:100, Zymed Labora-
tories Inc.) and visualized with a fluorescein-conjugated anti-rat
antibody.
RNA Isolation and RT-PCR—To analyze CD44 mRNA expression
levels, reverse transcription-polymerase chain reaction (RT-PCR) was
performed. First, ;1 3 106 C33A cells were seeded into a 10-cm dish
and transfected with either Vector-, PSM-RB-, or BRG-1-encoding plas-
mids along with pBabe. After 48 h of selection with puromycin, total
mRNA was isolated using TRIzol (Life Technologies, Inc.) according to
the manufacturer’s protocol. cDNAs were then synthesized using ;1 mg
of isolated total mRNA and the ThermoScript RT-PCR system (Life
Technologies, Inc.) following the manufacturer’s instructions. To am-
plify human CD44, cDNAs were subjected to PCR using the forward
primer: 59-CAGACCTGCCCAATGCCTTTGATGGACC-39 and the re-
verse primer: 59-CAAAGCCAAGGCCAAGAGGGATGCC-39. As a con-
trol, human glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
cDNA was amplified using the forward primer: 59-GGTCATCAATGG-
GAAACCCATCAC-39 and the reverse primer: 59-ACAAACTCTGC-
TACTTCTGG-39. PCR was performed with the following conditions:
94 °C, 1 min; 62 °C, 1 min; and 72 °C, 2.5 min, for 30 cycles. Approxi-
mately 10 ml of the PCR products were then separated by electrophore-
sis in a 1% agarose gel. The PCR products were visualized by ethidium
bromide staining and then photographed. The levels of GAPDH and
CD44 were quantitated using Metamorph software (Universal Imaging
Corp.) from two independent PCR reactions.
RESULTS
CD44 Expression Is Down-regulated in the C33A Cervical
Carcinoma Cell Line—CD44 is lost some in cervical carcino-
mas, and this loss correlates with increased metastatic poten-
tial (13, 14). We identified a human cervical carcinoma cell line,
C33A, which demonstrates loss of CD44 expression as deter-
mined by immunoblot analysis with a CD44-specific antibody
(Fig. 1A, lane 1). By contrast, the osteogenic sarcoma cell line,
SAOS-2, readily expresses detectable CD44 (Fig. 1A, lane 2).
Blotting for Cdk4 showed that equal total protein was loaded
(Fig. 1A). To examine whether loss of CD44 expression in C33A
occurred at the RNA level, RT-PCR analysis was used to ex-
amine the levels of CD44 mRNA in C33A cells versus the
CD44-positive SAOS-2 cells. In C33A cells, the levels of CD44
mRNA were ;20-fold less than that found in SAOS-2 (Fig. 1B,
lanes 3, 4, 5, and 6). Thus, CD44 expression in C33A is lost at
the level of RNA, suggesting that C33A cells either possess a
factor important for repressing CD44 expression or alterna-
tively lack a factor required for stimulating CD44 expression.
Factors Expressed by SAOS-2 Cells Act in-trans to Restore
CD44 Signaling in C33A Cells—To examine the underlying
difference in CD44 signaling between C33A and SAOS-2, we
utilized C33A-SAOS-2 (C-S) cell fusion lines that have been
previously characterized (32). Four independent C-S fusion
clones (#1–4) exhibited robust expression of CD44 comparable
to that observed in parental SAOS-2 cells (Fig. 2A, lanes 1–6).
Immunohistochemical analysis confirmed that CD44 expres-
sion was restored and appropriately localized in the cell fusions
(Fig. 2B, right panel). As a control, p53 staining confirmed that
FIG. 1. C33A cells have reduced CD44 expression. A, C33A (lane
1) and SAOS-2 (lane 2) cells were harvested and lysed, and equal total
protein was resolved by SDS-PAGE and immunoblotted for CD44 and
Cdk4. B, C33A cells were harvested as in A, total RNA was prepared,
and RT-PCR was performed utilizing 1 mg of total RNA as described
under “Materials and Methods.” As a control, PCR analysis of isolated
RNA was carried out from C33A (lane 1) and SAOS-2 (lane 2). The level
of CD44 RNA was normalized to that of GAPDH. The results are
representative of two independent RT-PCR experiments.
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the fusion expressed p53 protein (contributed from C33A nu-
clei), because SAOS-2 are p53-negative (Fig. 2B, left and mid-
dle panel). These findings suggest that C33A cells lack a fac-
tor(s) required for CD44 signaling, which is restored after
nuclear fusion with SAOS-2.
Loss of BRG-1 Correlates with Reduced CD44 Expression—A
known difference between SAOS-2 cells and C33A cells is that
SAOS-2 cells express BRG-1, a component of the SWI/SNF
complex involved in both gene regulation and chromatin re-
modeling, whereas C33A lack BRG-1 (36). To examine whether
loss of BRG-1 correlated with lack of CD44 expression, we
analyzed several tumor lines that were either positive or neg-
ative for BRG-1 expression. Immunoblot analysis revealed that
those tumor lines that were positive for BRG-1 were also pos-
itive for CD44 expression (Fig. 3A, upper and middle panel,
lanes 2, 3, 5, 6, and 7). However, the SW13 adenocarcinoma cell
line, which is BRG-1-negative, was deficient in CD44 protein
expression, similar to that observed in C33A cells (Fig. 3A,
upper and middle panel, lanes 1 and 4) (36). As a control, the
detection of actin shows the relative amount of protein loaded
per lane (Fig. 3A, lower panel, lanes 1–7). These data demon-
strate that loss of BRG-1 correlates with a lack of CD44 pro-
tein, suggesting that BRG-1 is required for CD44 expression.
BRG-1 Restores CD44 Expression in C33A and SW13
Cells—To determine whether BRG-1 is sufficient to induce
CD44 expression, BRG-1 was restored in BRG-1-negative
(C33A and SW13) cells. C33A and SW13 cells were cotrans-
fected with vector, a phosphorylation site mutant of RB (PSM-
RB) as controls, or BRG-1 along with a puromycin resistance
plasmid (pBabe-Puro). After selecting the transfected cells with
puromycin, cells were harvested and subjected to immunoblot
analysis. In C33A and SW13 cells, transfection of either vector
or PSM-RB did not alter CD44 levels. However, ectopic expres-
sion of BRG-1 caused a significant increase in CD44 protein
levels (Fig. 4A, upper panel, lanes 1–6). Immunoblotting for
BRG-1 and PSM-RB confirmed their expression in C33A and
SW13 cells, whereas Cdk4 levels indicate that equal total pro-
tein was loaded per lane (Fig. 4A, middle and lower panels,
lanes 1–6). Because RB has been shown to recruit BRG-1 for
transcriptional repression, we also examined whether expres-
sion of PSM-RB could alter BRG-1 stimulation of CD44. To test
this, we cotransfected PSM-RB with BRG-1 into C33A cells and
found that PSM-RB did not alter the ability of BRG-1 to mod-
ulate CD44 production (data not shown).
Because BRG-1 is known to mediate its function through
transcriptional regulation, we investigated whether BRG-1
stimulates CD44 mRNA levels (37). C33A cells were trans-
fected with either vector or PSM-RB along with pBabe-Puro
and selected in puromycin. RT-PCR analysis revealed that the
level of CD44 mRNA quantitated from vector-transfected cells
was equal to that of PSM-RB-transfected cells after normaliza-
tion to GAPDH (Fig. 4B, upper and lower panels, lanes 4, 5, 8,
and 9). In contrast, C33A cells transfected with BRG-1 showed
an ;40-fold induction in CD44 mRNA when compared with
that of vector- or PSM-RB-transfected cells and normalized
against GAPDH (Fig. 4B, upper and lower panels, lanes 4–9).
PCR analysis of the RNA prior to reverse transcribing revealed
no amplification, thus eliminating the possibility of DNA con-
tamination (Fig. 4B, upper and lower panels, lanes 1–3). The
effect of ectopic BRG-1 expression on the CD44 promoter was
assessed by reporter analysis in transient transfection assays.
Ectopic expression of BRG-1 did not stimulate CD44 reporter
activity, and high basal activity of the reporter was observed in
cells either expressing or deficient in BRG-1 (data not shown).
This finding is consistent with the idea that BRG-1 stimulates
transcription through the remodeling of chromatin, because we
show that BRG-1 clearly stimulates the expression of endoge-
nous CD44 RNA and protein.
Functional BRG-1 Is Required for Stimulating CD44 Produc-
tion—Because the data presented imply that BRG-1 may have
a role in maintaining the production of CD44, we investigated
whether BRG-1 is required for this process. To test this we
utilized an NIH3T3 cell line, called BO5-1, that inducibly ex-
presses dominant-negative BRG-1 (dnBRG-1) (28). The mutant
BRG-1 protein that is induced in BO5-1 cells contains a muta-
tion in the ATP-binding site that renders it catalytically inac-
tive, and in the presence of tetracycline, BO5-1 cells fail to
demonstrate detectable levels of dnBRG-1 (Fig. 5A, lanes 1 and
FIG. 3. Loss of BRG-1 correlates with a lack of CD44 expres-
sion. Thirty micrograms of lysate was isolated from subconfluent
SW13, U87, PC-3, C33A, SAOS-2, U2OS, and RD cells using an 8 M urea
extraction (8 M urea, 0.1 M NaH2PO4, 10 mM Tris, pH 8). The lysates
were then separated via SDS-PAGE and blotted for BRG-1, CD44, and
actin.
FIG. 2. Genetic determinants in SAOS-2 restore CD44 signaling in C33A. A, parental C33A and SAOS-2 cells along with four independent
C-S fusion clones were harvested and lysed, and equal total protein was resolved by SDS-PAGE and immunoblotted for CD44 and Cdk4. B,
immunohistochemical staining of both parental lines and a C-S fusion clone for p53 and CD44 expression. The results of this fusion clone are
representative of all other fusion clones tested.
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2). However, after incubation in the absence of tetracycline for
72 h, a strong induction of dnBRG-1 was observed. Immuno-
staining of the BO5-1 cells grown in the absence of tetracycline
revealed that expression of dnBRG-1 results in the reduction of
CD44 expression when compared with uninduced BO5-1 cells
(Fig. 5B). Microscopic analysis revealed that expression of dn-
BRG-1 significantly inhibits CD44 staining in ;90% of induced
cells when compared with BO5-1 cells grown in the presence of
tetracycline (Fig. 5C). These data imply that functional BRG-1
is required for stimulating CD44 expression.
Cyclin E Antagonizes BRG-1 Transcriptional Activity—It
has been previously reported that Cyclin E can bind to and
antagonize the ability of BRG-1 to induce growth arrest (38).
Based on this, and the findings that Cyclin E is also overex-
pressed in tumors, we examined whether expression of Cyclin
E could disrupt the ability of BRG-1 to signal to CD44 (39). To
test this, C33A cells were cotransfected with vector, BRG-1, or
BRG-1 and Cyclin E together with pBabe-Puro. After rapid
puromycin selection the cells were harvested and analyzed for
CD44 expression via immunoblotting. As expected, ectopic ex-
pression of BRG-1 in C33A stimulated CD44 expression when
compared with vector (Fig. 6, upper panel, lanes 1 and 2).
However, when Cyclin E was cotransfected with BRG-1 in two
independent transfections, CD44 expression was inhibited by
;62% as determined after normalization to Cdk4 (Fig. 6, upper
and lower panels, lanes 1, 3, and 4). Immunoblotting for BRG-1
and Cyclin E confirms their expression while Cdk4 levels were
monitored as a loading control (Fig. 6, middle and lower panels,
lanes 1–4). These findings show that Cyclin E can antagonize
the ability of BRG-1 to stimulate CD44 production.
DISCUSSION
Aberrant expression of CD44 is associated with advanced
tumor progression and poor clinical outcome (1–3). However,
little is known about what factors are required for maintaining
CD44 expression. Here we show that BRG-1 plays a critical role
in regulating CD44 transcription. Reintroduction of BRG-1
restored CD44 expression in BRG-1-negative (C33A and SW13)
cells, whereas expression of dominant-negative BRG-1 in
NIH3T3 cells inhibited CD44 production. Furthermore, ectopic
expression of Cyclin E inhibited the ability of BRG-1 to stimu-
late CD44, consistent with the notion that at least some com-
ponents of the cell cycle machinery could also mediate CD44
expression. These results indicate that BRG-1 is required for
regulating CD44 expression, suggesting that loss of BRG-1 may
contribute to the invasive and metastatic potential of certain
cancers.
BRG-1 plays a critical role in transcriptional regulation and
chromatin remodeling and can both stimulate and repress the
FIG. 4. BRG-1 stimulates CD44 expression in C33A and SW13
cells. A, C33A and SW13 cells were transfected with (1 mg) pBabe-Puro
and (15 mg) of vector (lane 1), PSM-RB (lane 2), or BRG-1 (lane 3).
Following puromycin selection, equal total protein was resolved by
SDS-PAGE and then immunoblotted for CD44, BRG-1, PSM-RB, and
Cdk4. B, C33A cells were transfected with vector (lanes 4, 5), BRG-1
(lanes 6 and 7), and PSM-RB (lanes 8 and 9) and then selected as
performed in A. Total RNA was prepared, and RT-PCR was performed
utilizing 1 mg of total RNA as described under “Materials and Methods.”
As a control, PCR analysis of isolated RNA was carried out from the
vector (lanes 1)-, BRG-1 (lane 2)-, and PSM-RB (lane 3)-transfected
cells. The level of CD44 RNA was normalized to that of GAPDH. The
results are representative of two independent RT-PCR experiments.
FIG. 5. BRG-1 is required for CD44 production. A, BO5-1 cells
were washed three times with PBS and then split into plates containing
media supplemented with and with out tetracycline (2 mg/ml). After 3
days, the cells were harvested and resolved by SDS-PAGE, and the
expression of dnBRG-1 was detected with an anti-Flag antibody. B,
immunohistochemical staining for CD44 in BO5-1 cells cultured either
in the presence or absence of tetracycline. C, quantitation of the immu-
nohistochemical staining in B.
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transcription of specific genes (22, 26–30, 32). BRG-1 is an
ATP-dependent chromatin remodeler that regulates transcrip-
tion through its ability to modify nucleosome structure (37).
Activation of CD44 expression is apparently dependent on
chromatin remodeling, because the dominant-negative BRG-1
used in this study specifically disrupts the ATPase activity of
BRG-1. In the case of CD44, BRG-1 likely converts the CD44
promoter from a transcriptionally inactive state to an active
one. The finding that transiently transfected CD44 reporter
constructs maintained high basal activity in the absence of
BRG-1 suggests that the plasmid-borne CD44 promoter con-
struct already exists in a transcriptionally active state, thus
masking any BRG-1 stimulatory effect at the level of chromatin
(data not shown).
The loss of CD44 expression by some tumors correlates with
increased metastatic potential (1). The mechanism of CD44 loss
in these tumors is largely unknown; however, in prostate car-
cinomas, CD44 expression is repressed through the methyla-
tion of the 59-CpG islands in the CD44 promoter (40). Interest-
ingly, loss of heterozygosity mapped to the 19p locus (which
overlaps with BRG-1) also occurs as a late-stage event in pros-
tate cancer (41). There are numerous ties between transcrip-
tional regulation, chromatin structure, and methylation. Three
SWI2/SNF2-like proteins, Mi-2, ATRX, and DDM1, have been
implicated in DNA methylation (42, 43). Specifically, DDM1
maintains genomic methylation through its ability to either
modify histones or increase the accessibility of DNA methyl-
transferase. The chromatin-remodeling activity of Mi-2 and
ATRX is thought to be targeted specifically to DNA to initiate
or maintain methylation-mediated transcriptional control.
However, it remains to be determined whether the recruitment
of SWI/SNF components to chromatin stimulates methylation
or if methylation is causative for the recruitment of specific
chromatin-remodeling activities. Therefore, determining
whether BRG-1 influences the methylation of the CD44 pro-
moter would be important in defining its mechanism of gene
regulation.
The importance of SWI/SNF in cancer is becoming increas-
ingly apparent. Recently, BRG-1 has been linked to breast
cancer by the finding that the coactivator function of BRCA1 on
p53 transcription is mediated through BRG-1 (30). In addition,
it has been shown that BRG-1 is required for RB signaling to
specific cell cycle targets (22, 32). Alteration of another SWI/
SNF subunit was identified after a genetic screen in malignant
rhabdoid tumors, where the hSNF5/INI1 gene located on the
long arm of chromosome 22, is either mutated or deleted in
rhabdoid tumors (44, 45). In addition, there is evidence that
loss of other SWI/SNF subunits like Baf 47, Baf 57, and Baf 155
occur in a variety of tumors; however, it remains to be deter-
mined whether loss of these other subunits affect tumorigene-
sis or CD44 expression (46).2 This study shows that BRG-1 is
required for enabling CD44 expression and provides a mecha-
nism through which CD44 is lost in cancer. These findings
suggest that BRG-1 loss may contribute to the formation of the
metastatic phenotype.
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